CTA_IIT_CRUSH PAD: Real-world Outcomes Following Use of the Shockwave Intravascular Lithotripsy (IVL) Technology in Calcified Common Femoral Lesions
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 50
- 试验地点
- 3
- 主要终点
- Change in Generic Health Status
研究概览
简要总结
The primary goal of the study is to obtain effect size data on the use of Shockwave Intravascular Lithotripsy (IVL) technology in calcified common femoral lesions in patients with peripheral artery disease for a series of endpoints, including target lesion revascularization and health status, to enable future planning of comparative effectiveness research.
详细描述
The primary objective of this study is to evaluate the generic health status outcomes and efficacy and safety outcomes following use of the Shockwave Intravascular Lithotripsy (IVL) technology in calcified common femoral lesions in patients with PAD seen in routine clinical practice.
The main testable hypothesis is that the use of IVL is associated with a health status improvement that is equal or higher than the threshold of a minimally clinically important difference on the EQ5D. Preliminarily data will be derived for the primary endpoint target lesion revascularization to enable future planning of larger comparative effectiveness research.
Secondary objectives of the study are to document procedural success following the use of IVL in common femoral lesions, disease stage change, as well as disease-specific health status in the real-world.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects presenting with claudication or CLI by Rutherford Clinical Category 2, 3, 4, 5, or 6 of the target limbs
- •Subject is a suitable candidate for angiography and endovascular intervention per the latest clinical guidelines
- •Patient is scheduled to undergo treatment with Shockwave Intravascular Lithotripsy (IVL) technology followed by standard of care treatment with DCB, BMS, DES at the physician's discretion.
- •Angiographic Inclusion Criteria
- •Target lesion that is located in a native, de novo common femoral artery
- •Target lesion reference vessel diameter is between 4.0mm and 7.0mm by visual estimate.
- •Target lesion is ≥70% stenosis by investigator via visual estimate.
- •Target lesion length is ≤50mm for lesions 70-99% stenosed. Target lesion can be all or part of the 50mm treated zone.
- •Chronic total occlusion, lesion length is ≤50mm of the total ≤50 mm target lesion.
- •Calcification is at least moderate defined as presence of fluoroscopic evidence of calcification: 1) on parallel sides of the vessel and 2) extending > 50% the length of the lesion if lesion is ≥50mm in length; or extending for minimum of 20mm if lesion is <50mm in length.
排除标准
- •Subjects with any medical condition that would make him/her an inappropriate candidate for treatment with Shockwave Medical Peripheral Lithoplasty® System as per Instructions for Use (IFU) or investigator's opinion.
- •Subject is already enrolled in other investigational (interventional) studies that would interfere with study endpoints.
- •Cognitive impairment as documented in medical records
- •Not speaking English or Spanish
- •Currently a prisoner
- •Pregnancy or nursing
- •Estimated survival less than 12 months at the time of screening
- •Prior history of CFA endarterectomy
研究组 & 干预措施
Shockwave Intravascular Lithotripsy (IVL)
Patients with calcified common-femoral artery disease, who are eligible to receive IVL per the FDA indications.
干预措施: Shockwave Intravascular Lithotripsy (IVL) (Device)
结局指标
主要结局
Change in Generic Health Status
时间窗: Baseline and 6 months
Generic Health Status will be measured using the EQ5D health status assessment. Descriptive system for health-related quality of life states in adults, consisting of five dimensions (Mobility, Self-care, Usual activities, Pain \& discomfort, Anxiety \& depression), each of which has five severity levels that are described by statements appropriate to that dimension. Higher scores indicate more severe or frequent problems.
Rate of Procedural Success
时间窗: Immediately post procedure
Procedural success defined as residual stenosis ≤30% without flow-limiting dissection (≥ grade D) prior to DCB
Change in Generic Health Status
时间窗: Baseline and 30 days
Generic Health Status will be measured using the EQ5D health status assessment. Descriptive system for health-related quality of life states in adults, consisting of five dimensions (Mobility, Self-care, Usual activities, Pain \& discomfort, Anxiety \& depression), each of which has five severity levels that are described by statements appropriate to that dimension. Higher scores indicate more severe or frequent problems.
次要结局
- Number of patients with new-onset MAEs(Up to 12 months)
- Number of Patients Free from TLR(Up to 12 months)
- Rate of Periprocedural clinical success(During admission, before discharge up to 48 hours)
- Change in Clinical Success(Baseline, 6 months and 12 months)
- Change in Clinical Success(Baseline and 30 days)